Total Funding
63
87
Total FundingPost-IPO Debt raised
Growth Score
-14 pts
Heat Score
36 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
141128
MindMaze formerly Relief Therapeutics develops biopharmaceutical and neurotechnology solutions for neurological and rare diseases.
- Marco Marotta: Chief Business Officer
Drew Cronin-Fine: Executive Director, Head of U.S. Marketing
About the Company
MindMaze formerly Relief Therapeutics combines neurotherapeutic software, proprietary hardware, wearables, sensors, digital assessments, telehealth capabilities, and therapeutic research to support motor and cognitive care across clinical and home settings. Its technology platform is designed to address conditions such as stroke, Parkinsons
disease, at-risk aging, spinal cord injury, multiple sclerosis, traumatic brain injury, and dementia related disorders, while also supporting pharmaceutical clinical trials through strategic collaborations.
